Three PARP inhibitors (olaparib, rucaparib, and niraparib) have been approved by the FDA for use in ovarian cancer (23, 24), and 2 PARP inhibitors (olaparib and talazoparib) have been approved for use in breast cancer (23). Here, PARP1 is linked to ovarian carcinoma.